
    
      Proof of concept trial evaluating safety and efficacy of treatment with Dolutegravir (DTG) +
      lamivudine (3TC) once daily in suppressed participants with history of previous treatment
      with 3TC or emtricitabine (FTC). Half of the participants will have history of failure with
      3TC or FTC and M184V/I or K65R/E/N mutations in previous plasma genotypes, although to be
      eligible these mutations cannot be detectable at study entry in proviral DNA.
    
  